Skip to content

A Study on New Blood Markers for Identifying Non Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

A Clinical Study to Explore Novel Biomarkers for Predicting Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075663
Enrollment
380
Registered
2024-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E086- Diabetes mellitus due to underlying condition with other specified complications

Interventions

Intervention1: NIL: NIL

Sponsors

Jamia Hamdard
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants with Diabetes defined as HbA1c less or equal to 6.5% or FPG 126mg/dL or taking anti-diabetic medication.

Exclusion criteria

Exclusion criteria: Individuals with a history of significant alcohol consumption-defined as more than 20 grams of alcohol per day for men and 10 grams per day for women,Individuals with a history of other liver diseases, such as viral hepatitis, autoimmune liver diseases, or liver cirrhosis,Pregnant individuals or those planning to become pregnant during the study period,Participants with severe comorbid conditions that could independently affect glucose metabolism or liver function (e.g., advanced chronic kidney disease, advanced heart failure),Individuals taking medications known to significantly impact glucose metabolism (e.g., corticosteroids) or liver function (e.g., methotrexate),Individuals with TB, any form of malignancies presents or history of HIV- AIDS or any disease that could impair the biomarkers levels,Participants with a history of major psychiatric disorders or cognitive impairment. Individuals currently taking medications that significantly impact glucose metabolism or biomarker levels (e.g., corticosteroids, certain antipsychotics),Individuals with a history of major surgery within the last six months,Individuals with acute infections or inflammatory conditions at the time of recruitment.

Design outcomes

Primary

MeasureTime frame
To measure the serum levels of Biomarkers in all the 4 groups and to correlate them with NAFLD severity assessed by Fibro Scan.Timepoint: Single Time point (Baseline)

Secondary

MeasureTime frame
To apply machine learning techniques to develop & validate predictive models for NAFLD & T2DM based on serum biomarkers & clinical features, & to compare their performance with conventional methodsTimepoint: Single Time point(Baseline)

Countries

India

Contacts

Public ContactDr Vineet Jain

JAMIA HAMDARD

makhan@jamiahamdard.ac.in9891026397

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026